Core Viewpoint - The company Hansa Biopharma-B (03378) has seen a nearly 6% rebound in its stock price following the approval of its innovative drug HX111 for clinical trials in China by the National Medical Products Administration [1] Group 1: Company Developments - Hansa Biopharma announced that its innovative drug injection HX111 has been approved for clinical trials in China [1] - HX111 is a first-in-class OX40-targeted antibody-drug conjugate (ADC), which has shown overexpression in several malignancies compared to normal tissues, making it a suitable target for ADC [1] - HX111 is the third first-in-class molecule to advance to clinical development, following HX009 and HX044, both of which are bispecific antibody therapies [1] Group 2: Market Reaction - Following the announcement, Hansa Biopharma's stock price increased by 5.12%, reaching HKD 18.08, with a trading volume of HKD 10.4874 million [1]
港股异动 | 翰思艾泰-B(03378)反弹近6% 创新药HX111获得国家药监局批准临床试验